Myelofibrosis Approved Drugs
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Myelofibrosis.
Found 4 Approved Drugs for Myelofibrosis
Ruxolitinib
Brand Names
Opzelura, Jakafi
Ruxolitinib
Brand Names
Opzelura, Jakafi
Form: Cream, Tablet
Method of administration: Oral, Topical
FDA approval date: November 16, 2011
Classification: Janus Kinase Inhibitor
Jakafi is a kinase inhibitor indicated for treatment of: intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis in adults.
Inrebic
Generic Name
Fedratinib
Inrebic
Generic Name
Fedratinib
Form: Capsule
Method of administration: Oral
FDA approval date: August 16, 2019
INREBIC ® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). INREBIC is a kinase inhibitor indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) ( 1 ).
Ojjaara
Generic Name
Momelotinib
Ojjaara
Generic Name
Momelotinib
Form: Tablet
Method of administration: Oral
FDA approval date: September 15, 2023
Classification: Kinase Inhibitor
OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. OJJAARA is a kinase inhibitor indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. ( 1 )
Vonjo
Generic Name
Pacritinib
Vonjo
Generic Name
Pacritinib
Form: Capsule
Method of administration: Oral
FDA approval date: February 28, 2022
Classification: Kinase Inhibitor
VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 × 10 9 /L. This indication is approved under accelerated approval based on spleen volume reduction [see Clinical Studies (1.
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances